Patient characteristics in the TL-post-CAR-T set at the time of enrollment in the DESCAR-T registry
| . | First progression after CAR T-cell therapy . | |
|---|---|---|
| N = 52 . | ||
| Age (y) | ||
| Median (min; max) | 65.5 (20; 81) | |
| Age ≥65 y | 29 | (55.8%) |
| Sex, male | 30 | (57.7%) |
| ECOG | ||
| 0-1 | 44 | (88.0%) |
| >2 | 6 | (12.0%) |
| Missing | 2 | |
| LDH > normal | ||
| No | 21 | (41.2%) |
| Yes | 30 | (58.8%) |
| Ann Arbor stage | ||
| I-II | 6 | (12.0%) |
| III-IV | 44 | (88.0%) |
| Missing | 2 | |
| aaIPI | ||
| 0 | 1 | (2.1%) |
| 1 | 17 | (36.2%) |
| 2 | 28 | (59.6%) |
| 3 | 1 | (2.1%) |
| Missing | 5 | |
| Histology | ||
| LBCL | 39 | (75.0%) |
| Transformed FL or other indolent | 12 | (23.1%) |
| PMBL | 1 | (1.9%) |
| HCT-CI-comorbidity evaluated | 52 | (100.0%) |
| At least 1 HCT-CI-comorbidity | 25 | (48.1%) |
| Nb of PLT before CAR T-cell therapy∗ | ||
| Median (min; max) | 2.0 (1; 6)† | |
| Prior autologous transplant | 5 | (9.6%) |
| Time from initial diagnosis to CAR T-cell therapy eligibility (y) | ||
| Median (min; max) | 1.46 (0.2; 21.0) | |
| Disease status before leukapheresis | ||
| Refractory | 41 | (85.4%) |
| Relapse | 7 | (14.6%) |
| Missing | 4 | |
| BT | 44 | (84.6%) |
| Disease status before CAR T-cell infusion | ||
| CR | 3 | (6.8%) |
| Partial response (PR) | 11 | (25.0%) |
| Stable disease | 4 | (9.1%) |
| Progressive disease | 25 | (56.8%) |
| Not evaluated | 1 | (2.3%) |
| CAR T product administered | ||
| Tisa-cel | 21 | (40.4%) |
| Axi-cel | 31 | (59.6%) |
| . | First progression after CAR T-cell therapy . | |
|---|---|---|
| N = 52 . | ||
| Age (y) | ||
| Median (min; max) | 65.5 (20; 81) | |
| Age ≥65 y | 29 | (55.8%) |
| Sex, male | 30 | (57.7%) |
| ECOG | ||
| 0-1 | 44 | (88.0%) |
| >2 | 6 | (12.0%) |
| Missing | 2 | |
| LDH > normal | ||
| No | 21 | (41.2%) |
| Yes | 30 | (58.8%) |
| Ann Arbor stage | ||
| I-II | 6 | (12.0%) |
| III-IV | 44 | (88.0%) |
| Missing | 2 | |
| aaIPI | ||
| 0 | 1 | (2.1%) |
| 1 | 17 | (36.2%) |
| 2 | 28 | (59.6%) |
| 3 | 1 | (2.1%) |
| Missing | 5 | |
| Histology | ||
| LBCL | 39 | (75.0%) |
| Transformed FL or other indolent | 12 | (23.1%) |
| PMBL | 1 | (1.9%) |
| HCT-CI-comorbidity evaluated | 52 | (100.0%) |
| At least 1 HCT-CI-comorbidity | 25 | (48.1%) |
| Nb of PLT before CAR T-cell therapy∗ | ||
| Median (min; max) | 2.0 (1; 6)† | |
| Prior autologous transplant | 5 | (9.6%) |
| Time from initial diagnosis to CAR T-cell therapy eligibility (y) | ||
| Median (min; max) | 1.46 (0.2; 21.0) | |
| Disease status before leukapheresis | ||
| Refractory | 41 | (85.4%) |
| Relapse | 7 | (14.6%) |
| Missing | 4 | |
| BT | 44 | (84.6%) |
| Disease status before CAR T-cell infusion | ||
| CR | 3 | (6.8%) |
| Partial response (PR) | 11 | (25.0%) |
| Stable disease | 4 | (9.1%) |
| Progressive disease | 25 | (56.8%) |
| Not evaluated | 1 | (2.3%) |
| CAR T product administered | ||
| Tisa-cel | 21 | (40.4%) |
| Axi-cel | 31 | (59.6%) |
ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; HCT-CI, hematopoietic stem cell transplant comorbidity index; LDH, lactate dehydrogenase; max, maximum; min, Minimum; PMBL, primary mediastinal B-cell lymphoma.
Up to 10 treatment lines can be collected from the register.
Ongoing query within the DESCAR-T registry for patients with only 1 line of prior treatment.